Silver triflate-catalyzed tandem reaction of 
N'-(2-alkynylbenzylidene)hydrazide with pyridyne

Lingyong Jiang, a Xingxin Yu, b Bing Fang,* a and Jie Wu*, b

 a College of Stomatology, Ninth People’s Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
 b Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China

braces_dr@hotmail.com; jie_wu@fudan.edu.cn

Supporting Information

1. General experimental method (S2)
2. Experimental procedure and characterization data (S2-S12)
3. 1H and 13C NMR spectra of compounds 3 and 4 (S13-S60)
General experimental methods:

Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63µm, standard grade). Analytical thin–layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25–35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ¹H and ¹³C NMR spectra were recorded in CDCl₃ on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

General experimental procedure for the silver triflate-catalyzed tandem reaction of N’-(2-alkynylbenzylidene)hydrazide with pyridyne.

A mixture of N’-(2-alkynylbenzylidene)hydrazide 1 (0.3 mmol) and AgOTf (10 mol %) in 1,4-dioxane (2.0 mL) was heated at 70 °C with vigorous stirring for 1 hour. Then, pyridyne precursor 2 (0.45 mmol, 1.5 equiv), CsF (0.9 mmol, 3.0 equiv), TEBAC (0.075 mmol, 0.25 equiv), and MeCN (2.0 mL) were added. The reaction mixture was
stirred at room temperature or 50 °C until completion of the reaction. The reaction mixture was diluted with ethyl acetate (5.0 mL), and quenched with water (5.0 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to provide the desired product.

6-Phenylpyrido[3′,4′:3,4]pyrazolo[5,1-a]isoquinoline 3a. $^1$H NMR (400 MHz, CDCl₃) δ 7.57-7.61 (m, 4H), 7.66 (t, $J = 7.6$ Hz, 1H), 7.79 (t, $J = 7.6$ Hz, 1H), 7.92 (d, $J = 8.2$ Hz, 1H), 7.98 (d, $J = 6.4$ Hz, 2H), 8.26 (d, $J = 6.0$ Hz, 1H), 8.43 (d, $J = 6.0$ Hz, 1H), 8.64 (d, $J = 7.8$ Hz, 1H), 9.50 (s, 1H); $^{13}$C NMR (100 MHz, CDCl₃) δ 114.5, 118.9, 119.0, 122.7, 125.8, 127.9, 128.0, 128.6, 128.8, 129.8, 129.9, 131.4, 133.3, 137.8, 138.7, 144.3, 144.8; HRMS calcd for C$_{20}$H$_{14}$N$_3$ (M$^+$+H): 296.1188, found: 296.1180.

6-Phenylpyrido[4′,3′:3,4]pyrazolo[5,1-a]isoquinoline 3a′. $^1$H NMR (400 MHz, CDCl₃) δ 7.58-7.64 (m, 4H), 7.73-7.77 (m, 2H), 7.85 (t, $J = 7.6$ Hz, 1H), 7.95-8.00 (m, 3H), 8.47 (d, $J = 6.4$ Hz, 1H), 8.76 (d, $J = 8.2$ Hz, 1H), 9.97 (s, 1H); $^{13}$C NMR (100 MHz, CDCl₃) δ 111.3, 114.9, 118.7, 123.6, 124.6, 128.0, 128.7, 129.1, 129.2, 129.6, 129.8, 130.0, 133.2, 138.7, 142.1, 146.1, 150.1; HRMS calcd for C$_{20}$H$_{14}$N$_3$ (M$^+$+H): 296.1188, found: 296.1181.
6-Cyclopropylpyrido[3′,4′:3,4]pyrazolo[5,1-\textit{a}]isoquinoline 3b. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 0.99-1.03 (m, 2H), 1.32-1.36 (m, 2H), 2.87-2.95 (m, 1H), 7.17 (s, 1H), 7.61 (t, $J = 7.3$ Hz, 1H), 7.71 (t, $J = 7.3$ Hz, 1H), 7.81 (d, $J = 7.8$ Hz, 1H), 8.22 (d, $J = 6.0$ Hz, 1H), 8.42 (d, $J = 5.5$ Hz, 1H), 8.55 (d, $J = 7.8$ Hz, 1H), 9.58 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 7.6, 11.9, 113.1, 114.6, 119.2, 122.6, 124.9, 127.2, 127.8, 128.0, 128.5, 130.9, 137.6, 141.2, 143.9, 144.9; HRMS calcd for C$_{17}$H$_{13}$N$_3$ (M$^+$+H): 260.1188, found: 260.1181.

6-Cyclopropylpyrido[4′,3′:3,4]pyrazolo[5,1-\textit{a}]isoquinoline 3b’. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 0.99-1.04 (m, 2H), 1.32-1.36 (m, 2H), 2.90-2.97 (m, 1H), 7.18 (s, 1H), 7.67 (t, $J = 7.3$ Hz, 1H), 7.75 (t, $J = 7.3$ Hz, 1H), 7.81-7.85 (m, 2H), 8.51 (d, $J = 6.0$ Hz, 1H), 8.66 (d, $J = 7.8$ Hz, 1H), 9.88 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 7.8, 110.8, 112.6, 115.1, 123.4, 123.9, 127.3, 128.2, 128.6, 129.4, 132.5, 141.2, 143.1, 146.6, 150.1; HRMS calcd for C$_{17}$H$_{13}$N$_3$ (M$^+$+H): 260.1188, found: 260.1170.

6-Butylpyrido[3′,4′:3,4]pyrazolo[5,1-\textit{a}]isoquinoline 3c. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.04 (t, $J = 7.3$ Hz, 3H), 1.56-1.60 (m, 2H), 1.91-1.99 (m, 2H), 3.32-3.36 (m, 2H), 7.32 (s, 1H), 7.61 (t, $J = 7.3$ Hz, 1H), 7.70 (t, $J = 7.6$ Hz, 1H), 7.83 (d, $J = 7.8$ Hz, 1H), 8.17 (d, $J = 5.5$ Hz, 1H), 8.40 (d, $J = 5.5$ Hz, 1H), 8.51 (d, $J = 7.8$ Hz, 1H), 9.52 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 14.0, 22.6, 28.8, 31.0, 114.6, 115.7, 119.0, 122.5,
125.1, 127.2, 127.7, 128.4, 130.8, 137.6, 139.8, 143.9, 144.8; HRMS calcd for C_{18}H_{18}N_{3} (M^+H): 276.1501, found: 276.1485.

6-Butylpyrido[4',3':4,3]pyrazolo[5,1-α]isoquinoline 3c. $^1$H NMR (400 MHz, CDCl$_3$) δ 1.03 (t, $J$ = 6.8 Hz, 3H), 1.53-1.58 (m, 2H), 1.91-1.95 (m, 2H), 3.30-3.34 (m, 2H), 7.31 (s, 1H), 7.64-7.76 (m, 3H), 7.83 (d, $J$ = 7.8 Hz, 1H), 8.49 (d, $J$ = 6.0 Hz, 1H), 8.57 (d, $J$ = 7.8 Hz, 1H), 9.81 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 14.0, 22.6, 28.8, 31.1, 110.8, 114.9, 115.3, 123.3, 123.9, 127.2, 128.1, 128.6, 129.3, 132.4, 139.8, 142.8, 146.4, 149.9; HRMS calcd for C_{18}H_{18}N_{3} (M^+H): 276.1501, found: 276.1483.

3-Fluoro-6-phenylpyrido[3',4':3,4]pyrazolo[5,1-α]isoquinoline 3d. $^1$H NMR (400 MHz, CDCl$_3$) δ 7.51-7.60 (m, 6H), 7.95-7.97 (m, 2H), 8.19 (d, $J$ = 5.5 Hz, 1H), 8.42 (d, $J$ = 5.5 Hz, 1H), 8.60-8.64 (m, 1H), 9.49 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 112.6 (d, $^{2}J_{CF}$ = 22 Hz), 114.2, 117.8 (d, $^{2}J_{CF}$ = 24 Hz), 117.9, 118.5, 122.5, 125.1 (d, $^{3}J_{CF}$ = 9 Hz), 128.7, 129.7, 130.2, 130.3, 131.2, 132.9, 137.9, 139.8, 144.4, 144.9, 161.8 (d, $^{1}J_{CF}$ = 248 Hz); HRMS calcd for C$_{20}$H$_{13}$FN$_{3}$ (M^+H): 314.1094, found: 314.1071.

3-Fluoro-6-phenylpyrido[4',3':4,3]pyrazolo[5,1-α]isoquinoline 3d*. $^1$H NMR (400 MHz, CDCl$_3$) δ 7.55-7.63 (m, 6H), 7.74 (d, $J$ = 6.0 Hz, 1H), 7.95-7.97 (m, 2H), 8.48-8.49 (m, 1H), 8.75-8.77 (m, 1H), 9.92 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ
111.2, 112.6 (d, $^2J_{CF} = 21$ Hz), 114.6, 117.6, 117.7, 118.4 (d, $^2J_{CF} = 24$ Hz), 121.5, 126.1 (d, $^3J_{CF} = 9$ Hz), 128.7, 129.8, 130.2, 131.3 (d, $^3J_{CF} = 9$ Hz), 133.0, 139.7, 143.0, 146.4, 150.2, 162.3 (d, $^1J_{CF} = 251$ Hz); HRMS calcd for C$_{20}$H$_{13}$FN$_3$ (M$^+$+H): 314.1094, found: 314.1097.

6-Cyclopropyl-3-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3e. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.01-1.05 (m, 2H), 1.34-1.39 (m, 2H), 2.91-2.98 (m, 1H), 7.13 (s, 1H), 7.46-7.50 (m, 2H), 8.19 (d, $J = 6.0$ Hz, 1H), 8.41-8.43 (m, 1H), 8.56-8.59 (m, 1H), 9.57 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 7.9, 11.9, 112.0 (d, $^2J_{CF} = 22$ Hz), 112.2, 114.5, 117.1 (d, $^2J_{CF} = 24$ Hz), 118.8, 121.7, 125.0 (d, $^3J_{CF} = 9$ Hz), 126.5, 129.7, 130.3 (d, $^3J_{CF} = 9$ Hz), 137.4, 142.5, 143.9, 161.7 (d, $^1J_{CF} = 248$ Hz); HRMS calcd for C$_{17}$H$_{13}$FN$_3$ (M$^+$+H): 278.1094, found: 278.1088.

6-Cyclopropyl-3-fluoropyrido[4',3':3,4]pyrazolo[5,1-a]isoquinoline 3e'. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.01-1.05 (m, 2H), 1.34-1.39 (m, 2H), 2.93-3.00 (m, 1H), 7.13 (s, 1H), 7.50-7.52 (m, 2H), 7.82 (d, $J = 6.0$ Hz, 1H), 8.51-8.53 (m, 1H), 8.66-8.70 (m, 1H), 9.86 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 8.0, 12.0, 110.9, 111.7, 111.9 (d, $^2J_{CF} = 22$ Hz), 114.8, 117.6 (d, $^2J_{CF} = 25$ Hz), 120.7, 125.9 (d, $^3J_{CF} = 10$ Hz), 131.3 (d, $^3J_{CF} = 10$ Hz), 132.4, 142.5, 143.2, 146.5, 150.2, 162.2 (d, $^1J_{CF} = 249$ Hz); HRMS calcd for C$_{17}$H$_{13}$FN$_3$ (M$^+$+H): 278.1094, found: 278.1085.
6-Butyl-3-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3f. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.04 (t, $J = 7.3$ Hz, 3H), 1.53-1.60 (m, 2H), 1.92-2.00 (m, 2H), 3.35-3.39 (m, 2H), 7.30 (s, 1H), 7.46-7.52 (m, 2H), 8.15 (d, $J = 5.5$ Hz, 1H), 8.42 (d, $J = 5.5$ Hz, 1H), 8.53-8.56 (m, 1H), 9.54 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 14.0, 22.6, 28.7, 31.1, 111.9 (d, $^{2}J_{CF} = 22$ Hz), 114.3, 114.9, 117.1 (d, $^{2}J_{CF} = 24$ Hz), 118.6, 121.9, 124.9 (d, $^{3}J_{CF} = 9$ Hz), 130.2 (d, $^{3}J_{CF} = 10$ Hz), 130.6, 137.7, 141.1, 144.1, 144.9, 161.6 (d, $^{1}J_{CF} = 248$ Hz); HRMS calcd for C$_{18}$H$_{17}$FN$_3$ (M$^+$+H): 294.1407, found: 294.1379.

![Image of 6-Butyl-3-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3f]

6-Butyl-3-fluoropyrido[4',3':3,4]pyrazolo[5,1-a]isoquinoline 3f*. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.04 (t, $J = 7.3$ Hz, 3H), 1.54-1.59 (m, 2H), 1.92-1.96 (m, 2H), 3.33-3.37 (m, 2H), 7.29 (s, 1H), 7.48-7.52 (m, 2H), 7.76 (d, $J = 4.2$ Hz, 1H), 8.51 (s, 1H), 8.61-8.64 (m, 1H), 9.81 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 14.0, 22.6, 28.8, 31.2, 110.7, 111.9 (d, $^{2}J_{CF} = 22$ Hz), 114.3, 117.5 (d, $^{2}J_{CF} = 23$ Hz), 120.8, 125.8 (d, $^{3}J_{CF} = 9$ Hz), 131.1 (d, $^{3}J_{CF} = 9$ Hz), 132.1, 141.0, 143.4, 146.5, 150.0, 162.1 (d, $^{1}J_{CF} = 249$ Hz); HRMS calcd for C$_{18}$H$_{17}$FN$_3$ (M$^+$+H): 294.1407, found: 294.1428.

![Image of 6-Butyl-3-fluoropyrido[4',3':3,4]pyrazolo[5,1-a]isoquinoline 3f*]

6-Cyclopropyl-2-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3g. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 1.01-1.05 (m, 2H), 1.34-1.39 (m, 2H), 2.94-2.96 (m, 1H), 7.13 (s, 1H), 7.46-7.50 (m, 2H), 8.19 (d, $J = 6.0$ Hz, 1H), 8.42 (d, $J = 5.5$ Hz, 1H), 8.56-8.60 (m, 1H), 9.58 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 7.9, 11.9, 112.0 (d, $^{2}J_{CF} = 22$ Hz), 112.2, 114.4, 117.1 (d, $^{2}J_{CF} = 24$ Hz), 118.8, 121.7, 125.0 (d, $^{3}J_{CF} = 9$ Hz), 130.3 (d, $^{3}J_{CF} = 9$ Hz), 130.7, 137.6, 142.6, 144.1, 144.9, 161.7 (d, $^{1}J_{CF} = 248$ Hz); HRMS calcd for C$_{17}$H$_{13}$FN$_3$ (M$^+$+H): 278.1094, found: 278.1107.

![Image of 6-Cyclopropyl-2-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3g]
6-Cyclopropyl-2-fluoropyrido[4',3':3,4]pyrazolo[5,1-a]isoquinoline 3g. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 1.01-1.05 (m, 2H), 1.33-1.39 (m, 2H), 2.94-2.99 (m, 1H), 7.14 (s, 1H), 7.45-7.54 (m, 2H), 7.81 (d, \(J = 6.0\) Hz, 1H), 8.52 (d, \(J = 6.0\) Hz, 1H), 8.67-8.71 (m, 1H), 9.87 (s, 1H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\) 8.1, 12.0, 110.9, 111.6, 111.9 (d, \(^2\)J\(_{CF}\) = 22 Hz), 114.7, 117.6 (d, \(^2\)J\(_{CF}\) = 24 Hz), 120.7, 125.9 (d, \(^3\)J\(_{CF}\) = 10 Hz), 131.3 (d, \(^3\)J\(_{CF}\) = 10 Hz), 132.4, 142.5, 143.2, 146.5, 150.2, 162.2 (d, \(^1\)J\(_{CF}\) = 249 Hz); HRMS calcd for C\(_{17}\)H\(_{13}\)FN\(_3\)(M\(^+\)+H): 278.1094, found: 278.1102.

6-Butyl-2-fluoropyrido[3',4':3,4]pyrazolo[5,1-a]isoquinoline 3h. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 1.04 (t, \(J = 7.3\) Hz, 3H), 1.54-1.60 (m, 2H), 1.90-1.98 (m, 2H), 3.31-3.34 (m, 2H), 7.30-7.37 (m, 2H), 7.80-7.84 (m, 1H), 8.09-8.10 (m, 2H), 8.42-8.43 (m, 1H), 9.53 (s, 1H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\) 14.0, 22.6, 28.7, 30.9, 107.7 (d, \(^2\)J\(_{CF}\) = 24 Hz), 114.1, 115.1, 116.7 (d, \(^2\)J\(_{CF}\) = 24 Hz), 119.2, 124.9, 126.1 (d, \(^3\)J\(_{CF}\) = 10 Hz), 129.5 (d, \(^3\)J\(_{CF}\) = 9 Hz), 129.9, 138.0, 139.2, 143.9, 144.7, 161.9 (d, \(^1\)J\(_{CF}\) = 247 Hz); HRMS calcd for C\(_{18}\)H\(_{17}\)FN\(_3\)(M\(^+\)+H): 294.1407, found: 294.1410.

6-Butyl-2-fluoropyrido[4',3':3,4]pyrazolo[5,1-a]isoquinoline 3h'. \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\) 1.04 (t, \(J = 7.3\) Hz, 3H), 1.53-1.60 (m, 2H), 1.94-2.01 (m, 2H), 3.38-3.42 (m, 2H), 7.41 (s, 1H), 7.44-7.48 (m, 1H), 7.81 (d, \(J = 6.0\) Hz, 1H), 7.91-7.94 (m, 1H), 8.31 (d, \(J = 7.3\) Hz, 1H), 8.55 (d, \(J = 5.0\) Hz, 1H), 9.86 (s, 1H); \(^{13}\)C NMR (100 MHz,
CDCl$_3$ δ 14.0, 22.6, 28.8, 31.1, 108.5 (d, $^2J_{CF} = 24$ Hz), 110.9, 114.8, 117.9 (d, $^2J_{CF} = 24$ Hz), 125.1 (d, $^3J_{CF} = 9$ Hz), 126.1, 129.8 (d, $^3J_{CF} = 9$ Hz), 131.7, 139.4, 143.4, 145.1, 146.2, 150.1, 162.0 (d, $^1J_{CF} = 247$ Hz); HRMS calcd for C$_{18}$H$_{17}$FN$_3$ (M$^+$+H): 294.1407, found: 294.1412.

2-Chloro-6-phenylpyrido[3′,4′:3,4]pyrazolo[5,1-a]isoquinoline 3i. $^1$H NMR (400 MHz, CDCl$_3$) δ 7.54-7.62 (m, 5H), 7.86 (d, $J = 8.7$ Hz, 1H), 7.96-7.97 (m, 2H), 8.23 (d, $J = 5.5$ Hz, 1H), 8.46 (s, 1H), 8.57 (s, 1H), 9.51 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 114.1, 118.1, 119.0, 122.1, 126.6, 126.8, 128.5, 128.7, 129.3, 129.7, 130.1, 130.3, 133.0, 134.8, 138.3, 139.0, 144.5, 145.1; HRMS calcd for C$_{20}$H$_{13}$ClN$_3$ (M$^+$+H): 330.0798, found: 330.0796.

2-Chloro-6-phenylpyrido[4′,3′:3,4]pyrazolo[5,1-a]isoquinoline 3i′. $^1$H NMR (400 MHz, CDCl$_3$) δ 7.32-7.35 (m, 1H), 7.59-7.62 (m, 3H), 7.69 (d, $J = 8.3$ Hz, 1H), 7.73-7.77 (m, 1H), 7.84 (d, $J = 7.3$ Hz, 1H), 7.92-7.97 (m, 2H), 8.53 (s, 1H), 8.72 (s, 1H), 9.94 (s, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 117.7, 120.5, 122.9, 127.9, 128.2, 128.7, 129.4, 129.8, 130.1, 130.2, 130.3, 133.1, 135.1, 139.0, 143.4, 146.3, 151.2; HRMS calcd for C$_{20}$H$_{13}$ClN$_3$ (M$^+$+H): 330.0798, found: 330.0792.

1-Chloro-13-phenyl-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,
3-azepine 4a. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 2.27 (s, 3H), 6.76 (s, 1H), 7.01 (d, $J$ = 8.3 Hz, 2H), 7.08 (s, 1H), 7.19 (d, $J$ = 8.2 Hz, 2H), 7.24 (d, $J$ = 6.0 Hz, 1H), 7.40-7.57 (m, 6H), 7.72 (d, $J$ = 6.9 Hz, 1H), 7.80 (d, $J$ = 6.0 Hz, 1H), 8.08-8.10 (m, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 21.5, 53.2, 62.0, 114.7, 120.5, 125.0, 127.4, 127.5, 127.6, 128.6, 129.1, 129.3, 129.9, 131.6, 131.9, 134.5, 135.5, 141.9, 145.1, 145.5, 147.9, 150.9, 167.0; HRMS calcd for C$_{27}$H$_{21}$ClN$_3$O$_2$S (M$^+$+H): 486.1043, found: 486.1043.

13-Butyl-1-chloro-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,3-b]azepine 4b. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 0.91 (t, $J$ = 7.2 Hz, 3H), 1.28-1.37 (m, 2H), 1.65-1.72 (m, 2H), 2.29 (s, 3H), 2.61-2.79 (m, 2H), 6.19 (s, 1H), 6.49 (s, 1H), 7.07 (d, $J$ = 7.8 Hz, 2H), 7.21 (t, $J$ = 7.3 Hz, 3H), 7.37-7.45 (m, 2H), 7.49 (d, $J$ = 6.9 Hz, 1H), 7.62 (d, $J$ = 7.3 Hz, 1H), 7.81 (d, $J$ = 5.5 Hz, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 13.8, 21.5, 22.4, 27.7, 37.9, 55.6, 61.4, 114.7, 121.0, 124.9, 127.3, 127.5, 128.4, 129.2, 129.9, 131.7, 134.7, 142.3, 145.1, 145.4, 147.8, 150.7, 172.7; HRMS calcd for C$_{25}$H$_{25}$ClN$_3$O$_2$S (M$^+$+H): 466.1356, found: 466.1345.

1-Chloro-9-methyl-13-phenyl-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,3-b]azepine 4c. $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 2.28 (s, 3H), 2.42 (s, 3H), 6.70 (s, 1H), 7.02-7.05 (m, 3H), 7.22-7.26 (m, 4H), 7.37 (s, 1H), 7.48-7.50 (m, 3H), 7.59 (d, $J$ = 7.8 Hz, 1H), 7.79 (d, $J$ = 6.0 Hz, 1H), 8.07-8.09 (m, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$) $\delta$ 21.5, 53.1, 62.0, 114.6, 120.6, 125.6, 127.4, 127.6, 128.8, 129.0, 129.1, 129.9, 131.5, 134.6, 135.6, 139.5, 142.0, 145.0, 145.5, 147.8, 150.9, 167.3; HRMS calcd for C$_{28}$H$_{23}$ClN$_3$O$_2$S (M$^+$+H): 500.1200, found: 500.1218.
1-Chloro-8-fluoro-13-phenyl-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,3-b]azepine 4d. $^1$H NMR (400 MHz, CDCl$_3$) δ 2.30 (s, 3H), 6.75 (s, 1H), 7.03-7.13 (m, 4H), 7.23-7.26 (m, 3H), 7.42-7.54 (m, 5H), 7.83 (d, $J = 5.5$ Hz, 1H), 8.06 (d, $J = 6.4$ Hz, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 21.5, 52.9, 61.4, 114.8 (d, $^2J_{CF} = 23$ Hz), 114.9, 116.0 (d, $^2J_{CF} = 22$ Hz), 120.5, 126.7 (d, $^3J_{CF} = 8$ Hz), 127.4, 127.5, 129.1, 130.0, 131.7, 133.9 (d, $^3J_{CF} = 8$ Hz), 134.5, 135.3, 137.7, 145.3, 145.5, 148.0, 150.8, 162.8 (d, $^1J_{CF} = 247$ Hz), 166.4; HRMS calcd for C$_{27}$H$_{20}$ClFN$_3$O$_2$S (M$^+$+H): 504.0949, found: 504.0968.

1-Chloro-9-fluoro-13-phenyl-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,3-b]azepine 4e. $^1$H NMR (400 MHz, CDCl$_3$) δ 2.30 (s, 3H), 6.75 (s, 1H), 7.03-7.13 (m, 4H), 7.23-7.26 (m, 3H), 7.42-7.54 (m, 5H), 7.83 (d, $J = 6.0$ Hz, 1H), 8.06 (d, $J = 7.3$ Hz, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$) δ 21.5, 52.9, 61.4, 114.8 (d, $^2J_{CF} = 23$ Hz), 114.9, 116.0 (d, $^2J_{CF} = 21$ Hz), 126.7 (d, $^3J_{CF} = 8$ Hz), 127.4, 127.5, 129.0, 129.1, 130.0, 131.7, 133.9 (d, $^3J_{CF} = 8$ Hz), 134.5, 135.3, 137.7, 145.3, 145.5, 148.0, 150.8, 162.8 (d, $^1J_{CF} = 247$ Hz), 166.4; HRMS calcd for C$_{27}$H$_{20}$ClFN$_3$O$_2$S (M$^+$+H): 504.0949, found: 504.0974.

13-Butyl-1-chloro-9-fluoro-5-tosyl-6,11-dihydro-5H-11,6-(azenometheno)benzo[e]pyrido[4,3-b]azepine 4f. $^1$H NMR (400 MHz, CDCl$_3$) δ 0.91 (t, $J = 7.3$ Hz, 3H),
1.28-1.37 (m, 2H), 1.64-1.71 (m, 2H), 2.32 (s, 3H), 2.61-2.79 (m, 2H), 6.17 (s, 1H), 6.46 (s, 1H), 7.11-7.13 (m, 3H), 7.20-7.28 (m, 4H), 7.57-7.60 (m, 1H), 7.83 (d, \( J = 6.0 \text{ Hz} \), 1H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \( \delta \) 13.8, 21.5, 22.3, 27.6, 37.8, 54.9, 61.2, 112.5 (d, \( ^{2}J_{\text{CF}} = 22 \text{ Hz} \)), 114.7, 115.3 (d, \( ^{2}J_{\text{CF}} = 22 \text{ Hz} \)), 120.4, 127.4, 129.1 (d, \( ^{3}J_{\text{CF}} = 8 \text{ Hz} \)), 130.1, 134.7, 144.6 (d, \( ^{3}J_{\text{CF}} = 8 \text{ Hz} \)), 145.3, 145.4, 148.0, 150.8, 162.9 (d, \( ^{1}J_{\text{CF}} = 250 \text{ Hz} \)), 172.9; HRMS calcd for C\(_{25}\)H\(_{24}\)ClF\(_{3}\)O\(_{2}\)S (M\(^{+}\)+H): 484.1262, found: 484.1252.
